CareDx Inc (CDNA) was Reiterated by Mizuho to “Buy” while Lowering the Price Target of the company shares to $ 8 from a previous price target of $12 . Mizuho advised their investors in a research report released on Jun 14, 2016.
On the company’s financial health, CareDx Inc reported $-0.37 EPS for the quarter, missing the analyst consensus estimate by $ -0.06 based on the information available during the earnings call on May 6, 2016. Analyst had a consensus of $-0.31. The company had revenue of $6.60 million for the quarter, compared to analysts expectations of $6.97 million. The company’s revenue was down -8.3 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.19 EPS.
CareDx Inc opened for trading at $4.81 and hit $6.08 on the upside on Friday, eventually ending the session at $5.93, with a gain of 11.47% or 0.61 points. The heightened volatility saw the trading volume jump to 21,864 shares. Company has a market cap of $83 M.
In a different news, on Jun 3, 2015, Peter Maag (CEO) purchased 2,000 shares at $4.84 per share price.
CareDx Inc. formerly XDx Inc. is a commercial-stage company which develops markets and delivers a diagnostic surveillance solution for heart transplant recipients. The Company’s commercialized testing solution the AlloMap heart transplant molecular test or AlloMap is a non-invasive blood-based test used to monitor heart transplant recipients for acute cellular rejection. AlloMap uses gene expression technology for the identification of heart transplant recipients. AlloMap provides a single integer score ranging from 0 to 40 and determines the probability of moderate to severe acute cellular rejection. As of December 31 2014 the Company performed more than 66000 commercial AlloMap tests in total. The Company is also engaged in the new product development in other areas of transplant surveillance such as the use of cell-free donor de-oxy ribonucleic acid (cfDNA) technology as a biomarker for rejection.